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Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive
Pulmonary Aspergillosis
Seyedmojtaba Seyedmousavi,a,b Johan W. Mouton,a,b Willem J. G. Melchers,a Paul E. Verweija
Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlandsa; Department of Medical Microbiology and Infectious Diseases,
Erasmus MC, Rotterdam, the Netherlandsb
We investigated the efficacy of posaconazole prophylaxis in preventing invasive aspergillosis due to azole-resistant Aspergillus
fumigatus isolates. Using a neutropenic murine model of pulmonary infection, posaconazole prophylaxis was evaluated using
three isogenic clinical isolates, with posaconazole MICs of 0.063 mg/liter (wild type), 0.5 mg/liter (F219I mutation), and 16 mg/
liter. A fourth isolate harboring TR34/L98H (MIC of 0.5 mg/liter) was also tested. Posaconazole prophylaxis was effective in A.
fumigatuswith posaconazole MICs of<0.5 mg/liter, where 100% survival was reached. However, breakthrough infection was
observed in mice infected with the isolate for which the posaconazole MIC was>16 mg/liter.
Invasive aspergillosis (IA) is an important opportunistic fungalinfection, especially among immunocompromised patients,
with an overall mortality ranging between 30 and 88% and up to
95% in patients underlying azole-resistant Aspergillus fumigatus
infections (1–5). Posaconazole (POS) is an extended-spectrum
triazole recommended for salvage therapy and prophylaxis of
aspergillus diseases in neutropenic patients with acute myeloid
leukemia (AML) or myelodysplastic syndrome (MDS) and in pa-
tients with graft-versus-host disease (GvHD) (6–8). The incidence
of invasive fungal diseases is significantly reduced in patients re-
ceiving POS prophylaxis (9, 10).
Over the past decade, acquired azole resistance in Aspergillus
fumigatus is increasingly recognized as an emerging problem (11,
12). Animal models and clinical experience indicate that infection
with an azole-resistant isolate is associated with azole treatment
failure (4, 12–27). Although azole resistance may develop during
azole therapy, the main route of resistance selection appears
through environmental exposure of A. fumigatus to azole fungi-
cides (28). Surveillance studies indicate that in areas of endemicity
up to two-thirds of patients with azole-resistant aspergillus dis-
eases have no history of azole therapy (4). Therefore, in areas of
environmental resistance, any patient at risk for IA can develop
azole-resistant disease (29).
POS has been shown to be effective for preventing IA and is
becoming a more common strategy to manage invasive fungal
infection in high-risk patients (9, 10, 30–32). However, the
efficacy of the drug in preventing IA due to azole-resistant
isolates is unknown, and to date only one case of breakthrough
IA due to azole-resistant A. fumigatus has been reported (18). In
this study, the patient was diagnosed with AML and developed IA
due to an A. fumigatus isolate with a TR34/L98H resistance mech-
anism and a POS MIC of 0.5 mg/liter. The breakthrough infection
developed despite adequate POS plasma levels (2.01 mg/liter)
(18).
We investigated the impact of azole resistance on the efficacy of
POS prophylaxis in preventing IA using an immunosuppressed
mouse model of pulmonary aspergillosis.
(Part of this research was presented at the 53rd Interscience
Conference on Antimicrobial Agents and Chemotherapy, Denver,
CO, 10 to 13 September 2013.)
MATERIALS AND METHODS
Fungal isolates. Four clinical A. fumigatus isolates were studied in a neu-
tropenic murine model of pulmonary infection. Three isolates were ob-
tained sequentially from respiratory samples of a patient with an aspergil-
loma (33). The first isolate exhibited a wild-type phenotype (POS MIC of
0.063 mg/liter) and harbored an A9T mutation in the CYP51A gene,
which was not associated with azole resistance. The patient was treated
with itraconazole, during which an F219I mutation was gained that cor-
responded with itraconazole resistance (MIC of 16 mg/liter) and low
POS resistance (MIC of 0.5 mg/liter). The patient was then treated with
POS, and a phenotype emerged which was POS highly resistant (MIC of
16 mg/liter) although no additional changes in the Cyp51A gene were
found (10). Microsatellite typing indicated that these isolates were iso-
genic (10). A fourth genetically unrelated isolate harboring the highly
prevalent TR34/L98H resistance mechanism with low POS resistance
(MIC of 0.5 mg/liter) was also investigated. This isolate was obtained from
a patient with proven IA and was previously evaluated in a nonneutro-
penic murine model of IA (24) (Table 1). Strain identification was con-
firmed by sequence-based analysis, as described previously (12). The iso-
lates were stored in 10% glycerol broth at80°C, and the inoculum was
prepared as described before (34). An in vitro antifungal susceptibility test
was performed based on the EUCAST guidelines using a broth microdi-
lution format (35).
In vitro kinetic growth assay. In order to rule out important fitness
costs associated with the acquisition of resistance mechanisms, the growth
characteristics of the four isolates were determined using a previously
described microbroth kinetic system (36). Briefly, the inocula were pre-
pared by diluting an overnight culture grown on agar plates with 0.9%
NaCl to 1  106 to 5  106 CFU/ml. The fungal suspensions were then
further diluted in RPMI 1640 medium (with L-glutamine, without so-
dium bicarbonate) (Sigma, USA) supplemented with 0.165 M morpho-
linepropanesulfonic acid (MOPS) to give a final inoculum between 0.5
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103 and 2.5 103 CFU/ml. Fungal inoculum (100 l) was added to each
well of a sterile 96-well flat-bottomed microtiter plate containing RPMI
1640 medium (100l/well). Inoculations were performed in duplicate for
each isolate, and two wells contained only medium (background control).
After inoculation, the microtiter plates were agitated for 15 s and incu-
bated at 35 to 37°C inside a plate reader (Rosys Anthos HT3; Anthos
Labtec Instruments GmbH, Salzburg, Austria) for 72 h under ambient
conditions. The optical density at 405 nm (OD405) was automatically
recorded for each well every 30 min without shaking. The changes in ODs
over time were used to generate growth curves. The background ODs (the
ODs of growth control wells) were subtracted from the ODs of the inoc-
ulated wells, and then the growth curve was plotted against time.
Infection model. A total of 264 outbred CD-1 (Charles River, the
Netherlands) female mice, 4 to 5 weeks old, weighing 20 to 25 g, were
randomized into groups of 11 mice for POS prophylaxis. To render the
mice neutropenic, cyclophosphamide (150 mg/kg on days4 and4 and
100 mg/kg on day1) was administered. Animals were treated from day
2 to 7 days postchallenge with 1, 4, 8, 16, and 32 mg/kg oral POS (Merck
B.V., the Netherlands) once daily. Clinical trials support once- or twice-
daily dosing based on the long elimination phase half-life of POS (37).
On day zero and 2 h after POS therapy, mice were infected with the A.
fumigatus isolates through instillation of the inoculum, corresponding to
a 90% lethal dose (LD90) of each isolate, in the nares using a procedure
described before (38, 39). The inoculum used was 7 106 (V74-61, wild
type; POS MIC of 0.063 mg/liter), 3 107 (V76-03, F219I mutation; POS
MIC of 0.5 mg/liter), 1 107 (V79-63, F219I mutation; POS MIC of16
mg/liter), and 1  107 (V52-35, TR34/L98H mutation; POS MIC of 0.5
mg/liter) conidia, respectively. The LD90 was separately determined for
each isolate.
Postinfection viability counts of the injected inocula were deter-
mined to ensure that the correct inocula had been injected. The ani-
mals were housed under standard conditions, with drink and feed
supplied ad libitum.
The animal studies were conducted in accordance with the recom-
mendations of the European Community (Directive 2010/63/EU revising
Directive 86/609/EEC on the protection of animals used for scientific
purposes adopted on 22 September 2010), and all animal procedures were
approved by the Animal Welfare Committee of Radboud University (RU-
DEC 2011-174).
Survival in days postinfection was recorded for each mouse in each
group and was considered the primary outcome effect measure to assess
the therapeutic efficacy of POS prophylaxis (40). The infected mice were
examined at least three times daily. These clinical inspections were carried
out in order to ensure that there were no cases of dehydration, torticollis,
staggering, high weight loss (a decrease of 15% within 48 h or 20% within
24 h), or drop in body temperature to below 33°C. Mice demonstrating
these signs of disease were humanely terminated. On day 15 postinfection,
all remaining surviving mice were humanely euthanized under isoflurane
anesthesia, and blood and internal organs were collected.
PKanalysis of POSprophylaxis inmice.The procedure and pharma-
cokinetic (PK) parameters for POS prophylaxis are described in our pre-
vious study (39). Briefly, a total of 96 outbred CD-1 (Charles River, the
Netherlands) female mice, 4 to 5 weeks old, weighing 20 to 22 g, were used
to establish immunosuppressed pulmonary infection, as described above.
Blood and bronchoalveolar lavage (BAL) samples were drawn at eight
predefined time points postinfection (0, 0.5, 1, 2, 4, 8, 12, and 24 h; 3 mice
per each time point) and stored at 80°C (39). POS concentrations in
plasma and BAL fluid were measured by a validated (for human and
mouse matrices) ultraperformance liquid chromatography (UPLC)
method with fluorescence detection, as described elsewhere (41). Geo-
metric mean concentrations of total POS in plasma were calculated for
each time point (n 3 mice). Peak concentrations in plasma (Cmax) were
directly observed from the data. Pharmacokinetic parameters were de-
rived using noncompartmental analysis with Phoenix, version 6.2 (Phar-
sight, Inc.). The area under the plasma concentration-time curve (AUC)
from time zero to 24 h post infusion (AUC0 –24) was determined by use of
the log-linear trapezoidal rule. The elimination rate constant was deter-
mined by linear regression of the terminal points of the log-linear plasma
concentration-time curve. The terminal half-life was defined as ln2 di-
vided by the elimination rate constant. Clearance (CL) was calculated as
dose/AUC0 –24. Concentrations of total POS in BAL fluid from three mice
per time point were determined as described previously (41). Urea in BAL
aspirate and plasma was measured utilizing a modified enzymatic assay
(QuantiChrom urea assay kit, DIUR-500; BioAssay Systems) (42, 43). The
concentration of POS in epithelial lining fluid (ELF) was then determined
by using the ratio of the urea concentration in BAL fluid (ureaBAL) to that
in plasma (ureaplasma) as described previously (38, 39, 42–47): drug con-
centrationELF drug concentrationBAL ureaplasma/ureaBAL.
Statistical analysis. All data analyses were performed using GraphPad
Prism, version 5.0, software for Windows (GraphPad Software, San Di-
ego, CA). The significance of the differences between growth characteris-
tics of four isolates, including lag phase, first transition phase, log phase,
and second transition phase, was determined using one-way analysis of
variance (ANOVA), followed by Bonferroni’s multiple-comparison test.
Mortality data were analyzed by a log rank test. Dose/MIC and AUC0 –24/
MIC ratios were calculated by dividing the dose (in milligrams per kilo-
gram of body weight) or the AUC by the MIC. The dose, Cmax, and
AUC0 –24/MIC ratio data were log10 transformed to approximate a normal
distribution prior to statistical analysis. The relationship between the in
vivo prophylaxis (survival), dose, and AUC0 –24/MIC was determined by
nonlinear regression analysis and the Hill equation, with a variable slope
fitted to the data both for each individual isolate and for pooled survival
data, with the maximum effect (maximum survival) constrained at
100%. The fits were performed for survival data of each strain and all
strains simultaneously. The goodness of fit was checked by use of the R2
value and visual inspection. Statistical significance was defined as aP value
of 0.05 (two-tailed). The probability of expected pharmacodynamic
(PD) target attainment (AUC/MIC) of POS prophylaxis versus treatment
was determined for a range of A. fumigatus MICs, as described previously
(48). In addition, the 50, 80, and 90% effective pharmacodynamic indices
(EI50, EI80 and EI90, respectively) of the 24-h area under the concentra-
tion-time curve (AUC) of POS best correlating with efficacy were deter-
mined. For comparison, an F test was performed to define whether the
best-fit values (log 50% effective dose [ED50]) differed between the four
groups.
The treatment data used in Fig. 4 was obtained from our previously
published study (24), for which an EI50 of 184.2 (95% confidence interval
[CI], 33.21 to 1,022) was shown to be the optimal pharmacodynamic
index to treat disseminated infection caused by the A. fumigatus isolate
(V52-35) for which the POS MIC was 0.5 mg/liter.
TABLE 1 Characteristics of four A. fumigatus isolates used in the
prophylaxis model
Isolate
no.a
Strain
no.
Prior azole
exposure
Cyp51A
substitution(s)b
MIC (mg/liter)c
AMB ITC VRC POS
1 V74-61 ITC A9T 1 0.5 1 0.063
2 V76-03 ITC A9T, F219I 1 16 1 0.5
3 V79-63 POS A9T, F219I 1 16 8 16
4 V52-35 No TR34/L98H 1 16 4 0.5
a Isolates 1, 2, and 3 were isogenic and recovered from an aspergilloma patient (29).
Isolate number 4 was unrelated to isolates 1 to 3 and was obtained from a patient with
proven invasive aspergillosis.
b Isolates 1 to 3 harbored an A9T mutation Cyp51A, but this was found not to be
associated with a change of the susceptibility to azoles. The F219I mutation was found
to be associated with itraconazole resistance (29).
c During POS therapy the phenotype changed for voriconazole (VRC) and
posaconazole (POS), but this change was not associated with a subsequent mutation in
the cyp51A gene, suggesting another, yet unknown, resistance mechanism. AMB,
amphotericin B; ITC, itraconazole.
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RESULTS
In vitro susceptibility and fitness. The characteristics and in vitro
susceptibilities of the four A. fumigatus isolates are shown in Table
1. All isolates grew well after 48 h of incubation at 35 to 37°C. The
three isolates showed increasing POS MICs although the increase
from 0.5 mg/liter to 16 mg/liter was not associated with addi-
tional mutations in the cyp51A gene. Growth curves did not differ
in shape and growth rates between the wild-type and two POS-
resistant isogenic A. fumigatus isolates. Similar growth character-
istics were also observed for the nonisogenic isolate harboring the
TR34/L98H resistance mechanism (data not shown).
PK of POS. The PK parameters of POS prophylaxis are shown
in Table 2. The penetration of POS in ELF based on total drug was
between 20.21 and 31.39%. At the range of 4 to 32 mg/kg dosing
regiments, the total AUC0 –24/MIC was 145.4 to 581 in plasma and
29.38 to 157.56 in ELF for the isolates with MICs of0.5 mg/liter.
As a comparison, the recommended dose of the oral suspen-
sion of POS is 200 mg three times a day for the prophylaxis of
invasive fungal infections, which corresponds to an AUC of
115.06 mg · h/liter and a Cmax of 0.58 mg/liter in plasma (6).
Efficacy of POS prophylaxis. (i) Survival curves. Figure 1
shows the survival curves of POS-treated mice by dose. The sur-
vival curves for all control groups receiving 0.9% saline orally
showed a mortality of 100%. The survival at day 10 postinfection
was significantly better for POS-treated mice than for controls
(Fig. 1). A dose-response relationship was observed for each iso-
late. The maximum effect (100% survival) was reached at a dose of
16 mg/kg for the isolates with MICs of0.5 mg/liter, independent
of the corresponding genotype. Yet for the isolate with the POS
MIC of16 mg/liter, maximum effect was lower (less than 70%)
than for other isolates, even with the highest dose (32 mg/kg).
(ii) Dose-response analysis. The dose-response curves for
dosing regimens and control groups of POS prophylaxis are
shown in Fig. 2. POS prophylaxis improved the survival of the
mice in a dose-dependent manner. A dose-response relationship
was observed that depended on the POS dose level but was inde-
TABLE 2 Pharmacokinetic parameters of POS in plasma and ELF
following 3 days of once-daily oral administration of 4, 8, 16, and 32
mg/kg in immunosuppressed micea
POS dose
(mg/kg)
Cmax
(mg/liter)
AUC0–24
(mg · h/liter)
Cmax in
ELF/Cmax
in plasma
ratio (%)
AUC0–24 in
ELF/AUC0–24
in plasma
ratio (%)Plasma ELF Plasma ELF
4 5.51 1.58 72.69 14.69 28.68 20.21
8 8.7 2.83 149.80 42.14 32.53 28.13
16 10.92 3.62 198.90 62.23 33.15 31.29
32 15.04 5.32 290.50 78.78 35.37 27.12
a For comparison, in humans the Cmax and AUC0 –24 values were 0.58 mg/liter and
15.06 mg · h/liter, respectively, with a dosing regimen of 200 mg three times daily (6).
FIG 1 Efficacy of posaconazole prophylaxis against 4 A. fumigatus isolates. Three isogenic isolates harboring A9T and F219I point mutations in the cyp51A gene
with POS MICs of 0.063 (V74-61), 0.5 (V76-03), and 16 mg/liter (V79-63) were obtained sequentially from a patient with aspergilloma under prolonged
antifungal therapy. Isolate number 4 (V52-35) was obtained from a patient with proven IA without prior azole exposure and was genetically different, with a POS
MIC of 0.5 mg/liter. This isolate harbored a TR34/L98H resistance mechanism in the Cyp51A gene. Animals were treated daily from day 2 to 7 days
postchallenge with doses of posaconazole ranging from 1 to 32 mg/kg once daily and observed for 14 days. Placebo groups received only 0.9% saline. For all
groups, n 11.
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pendent of the genotypes and azole resistance mechanisms. The
Hill equation with a variable slope fitted the relationship between
the dose and 10-day survival data well, with R2 values of 0.96
(V74-61, wild type; MIC of 0.63 mg/liter POS), 0.98 (V76-03,
F219I mutation; MIC of 0.5 mg/liter POS), 0.95 (V79-63, F219I
mutation; MIC of 16 mg/liter POS), and 0.97 (V52-35, TR34/
L98H mutation; MIC of 0.5 mg/liter POS), respectively. The 50%
effective dose (ED50) was 3.35 mg/kg (95% confidence interval
[CI], 2.19 to 5.12 mg/kg), 2.83 mg/kg (95% CI, 1.81 to 4.43 mg/
kg), and 14.08 mg/kg (95% CI, 9.06 to 21.90 mg/kg) for three
genetically identical isolates with wild type phenotype and low and
high POS resistance, respectively, and 3.03 mg/kg (95% CI, 1.91 to
4.80 mg/kg) for the isolate with different genotype and low resis-
tance to POS.
(iii) Exposure-response analysis. The AUC for each dose, de-
termined from PK experiments (Table 2), was used to calculate
the AUC0 –24/MIC ratio for each isolate, as shown in Fig. 3. The
exposure-response relationship had a sigmoidal shape. Increased
POS exposure was required to obtain maximum efficacy in mice
infected with the isolate with a MIC of16 mg/liter compared to
those infected with the isolate with a MIC of0.5 mg/liter.
The Hill-type model with a variable slope fitted the relation-
ship between the 24-h AUC/MIC ratio and 14-day survival well,
with an R2 value of 0.77 (P  0.05). The 50% effective AUC for
POS prophylaxis was 37.38 (95% confidence interval [CI], 7.130
to 196). We also determined the relationship between the in vivo
efficacy and the peak levelCmax/MIC (50% effective concentration
[EC50] of 1.74; CI, 0.073 to 41.28; R
2 value of 0.76). However, the
FIG 2 Fourteen-day survival as a function of posaconazole dose against four A. fumigatus isolates. Shown are data for the three isogenic isolates harboring A9T
and F219I point mutations in the cyp51A gene with POS MICs of 0.063 mg/liter (V 74-61), 0.5 mg/liter (V 76-03), and16 mg/liter (V 79-63) and for a genetically
different isolate with a POS MIC of 0.5 mg/liter (V52-35) harboring the TR34/L98H resistance mechanism. POS prophylaxis improved the survival of the infected
mice in a dose-dependent manner for all four isolates. The curves indicate fits with the Hill equation for each isolate. ED50, 50% effective dose.
FIG 3 Percent survival as a function of the POS AUC0 –24/MIC. The curve is the model fit with the Hill equation for each datum.
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AUC0 –24/MIC appeared to be the most important pharmacody-
namic index correlating with prophylaxis, which was significantly
different between A. fumigatus isolates with POS MICs of 0.5
mg/liter and the isolate with a POS MIC of 16 mg/liter (P 
0.05).
Notably, in the current prophylaxis study, the 50% effective total
AUC0–24/MIC was 93.58 (95% CI, 13.90 to 629.9) in order to prevent
invasive pulmonary infection caused by the A. fumigatus isolate (V
52-35) for which the POS MIC was 0.5 mg/liter. However, in
preclinical treatment studies, we have previously shown that a
two-times-higher exposure was required to treat infection caused
by this isolate (EI50 of 184.2 [95% CI, 33.21 to 1,022]) (Fig. 4).
(iv) Comparative efficacy of POS prophylaxis against the
four isolates. In order to compare the efficacy of POS prophylaxis
in preventing infection caused by the different isolates, the best-fit
values for the curves were defined based on the EI50, EI80, and EI90
of the AUC of POS and compared to each other (Table 3). The
efficacy of POS prophylaxis was significantly different between A.
fumigatus isolates with POS MICs of0.5 mg/liter and the isolate
with a POS MIC of16 mg/liter (P 0.05). The null hypothesis
was rejected in an F test (P  0.0014, F  10.72, degrees of free-
dom, numerator [dfn]  3; degrees of freedom, denominator
[dfd]  11), indicating that EI50 was significantly different (Ta-
ble 3).
DISCUSSION
Our model indicated that the efficacy of POS prophylaxis in low-
resistant isolates (MIC of 0.5 mg/liter) was similar to that of mice
infected with the isolate with the wild-type phenotype. In a previ-
ous study that investigated the efficacy of POS treatment of azole-
resistant isolates, we observed that the efficacy of POS was reduced
in mice infected with the isolate harboring the TR34/L98H resis-
tance mechanism (MIC of 0.5 mg/liter) compared to that of mice
infected with a wild-type isolate, indicating that higher doses of
POS were required to achieve efficacy similar to that for the wild-
type-infected mice (24). Our current model indicates that when
FIG 4 Fourteen-day survival as a function of the posaconazole AUC/MIC ratio for the A. fumigatus isolates with a POS MIC 0.5 mg/liter in treatment versus
prophylaxis studies. In the current prophylaxis study (right graph), the 50% effective total AUC0 –24/MIC was 93.58 (95% CI, 13.90 to 629.9) in order to prevent
invasive pulmonary infection caused by the A. fumigatus isolate (V 52-35) with the POS MIC of 0.5 mg/liter. The treatment data (left graph) was obtained from
our previously published study (24), for which the EI50 of 184.2 (95% CI, 33.21 to 1022) was shown to be the optimal pharmacodynamic index to treat
disseminated infection caused by the A. fumigatus isolate (V 52-35) with the POS MIC of 0.5 mg/liter.
TABLE 3 The comparison of efficacy of POS prophylaxis between four A. fumigatus isolates based on the EI50, EI80, and EI90 values of the 24-h
AUCa
MIC group and A. fumigatus strain
(mutation [POS MIC])b EI50 (95% CI) EI80 (95% CI) EI90 (95% CI)
MIC 0.5 mg/liter
V 74-61 (A9T [0.63]) 16.36 (12.18 to 21.97) 31.85 (21.16 to 47.94) 47.03 (26.14 to 84.61)
V 76-03 (A9T F219I [0.5]) 13.60 (9.29 to 19.91) 29.18 (18.87 to 45.12) 45.60 (23.40 to 88.88)
V 52-35 (TR34/L98H [0.5]) 13.81 (8.92 to 21.38) 33.80 (21.68 to 52.70) 57.06 (28.95 to 112.5)
MIC 16
V 79-63 (A9T F219I [16]) 51.22 (38.44 to 68.24) 135.8 (74.38 to 247.9) 240.2 (96.39 to 598.5)
P valuec 0.0014 0.0002 0.0044
F test (dfn, dfd) 10.72 (3, 11) 17.84 (3, 11) 7.859 (3, 11)
a See reference 33.
b All MIC values are in mg/liter.
c For all isolates, differences between prophylactic efficacy of isolates with MICs of0.5 mg/liter and the isolate with a MIC of16 mg/liter were significant.
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POS is given as prophylaxis, the efficacy against isolates with a POS
MIC of 0.5 mg/liter is similar to that of the wild-type isolate.
It has been reported that the POS levels in the lung, at the site of
infection/colonization, are relatively high (49, 50), which is con-
sistent with the drug’s lipophilic characteristics and its increased
intracellular permeability (51, 52). In our model we previously
reported high POS levels in epithelial lining fluid, which might
explain the high efficacy against low-POS-resistant isolates (38,
39). However, reduced efficacy was observed in isolates with high
POS resistance (MIC of16 mg/liter).
It is unlikely that differences in POS efficacies were due to
differences in A. fumigatus fitness levels. Although the acquisition
of resistance mechanisms during azole therapy has been associ-
ated with a fitness cost (53), isolates with resistance mechanisms in
the cyp51A gene were shown to be as virulent as wild-type controls
(54). In our current study we selected three isogenic isolates with
increasing POS MICs and demonstrated similar in vitro growth
characteristics, which indicates that the acquisition of a resistance
mechanism was not associated with a fitness cost.
The exposure-response relationships of POS have been defined
previously in experimental models of aspergillus infections (24,
25, 55), for which a total AUC0 –24/MIC ratio between 167 and 178
was predictive of half-maximal efficacy, given that only the un-
bound fraction of a drug in serum/plasma is pharmacologically
active. Considering the high degree of POS protein binding in
plasma (98 to 99%) and negligible protein binding in ELF, the
results of the current study indicated that effective local concen-
trations (less than 50% survival) might be achieved even at the
lowest dose (4 mg/kg), with a free AUC0 –24/MIC ratio of 1.45 in
plasma and 14.69 in ELF. Our model indicates that this level is
high enough to prevent infection with A. fumigatus isolates with
MICs of 0.5 mg/liter (Fig. 4). However, for the isolates with
higher POS MICs (16 mg/liter), the obtained free AUC0 –24/MIC
was 0.18 in plasma and 4.92 in ELF at highest dose (32 mg/
liter), which indicates the possibility of breakthrough IA. Given
that a significant proportion of isolates harboring an azole resis-
tance mechanism exhibit a POS MIC of 0.5 mg/liter (56), the
effective exposure is highly probable to be achieved with the rec-
ommended dose of POS.
In a recent large international surveillance study, including 22
centers from 19 countries, the proportion of azole-resistant clin-
ical A. fumigatus isolates was 3.4% (range, 0 to 26.1% per center)
(J. W. M. van der Linden, M. C. Arendrup, A. Warris, K. Lagrou,
H. Pelloux, P. M. Hauser, E. Chryssanthou, E. Mellado, S. E. Kidd,
A. M. Tortorano, E. Dannaoui, P. Gaustad, J. W. Baddley, A.
Uekötter, C. Lass-Flörl, N. Klimko, C. B. Moore, D. W. Denning,
A. C. Pasqualotto, C. Kibbler, S. Arikan-Akdagli, D. Andes, J. Me-
letiadis, L. Naumiuk, M. Nucci, W. J. G. Melchers, and P. E. Ver-
weij, submitted for publication). Among the isolates with an az-
ole-resistant phenotype, 50% exhibited a POS MIC of 0.5 mg/
liter which according to our model could be prevented with POS
prophylaxis. Given the above-mentioned epidemiology, in cen-
ters that choose to give POS prophylaxis to high-risk patients, the
probability of breakthrough infection due to azole-resistant A.
fumigatus appears to be very low.
Notably, the size of inoculum used for infection in the current
preclinical study may not seem to represent human infections.
However, the concordance of PK/PD index magnitudes obtained
from this model and humans has been demonstrated in terms of
efficacy and pharmacokinetics of antifungals against A. fumigatus
infections, using survival as primary endpoint (22–24, 34, 39, 57).
Thus, the results of our study can be useful in a human setting.
We conclude that POS is effective in preventing invasive pul-
monary aspergillosis in our immunocompromised mouse model.
However, our model indicates that treatment does not prevent the
full range of POS resistance phenotypes. Possibly higher exposure
can be obtained using the new formulations, i.e., a POS tablet,
which may then also enable prevention of infection due to A.
fumigatus isolates highly resistant to POS.
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